OK, I understand that there was no mention of “median”. I suppose I read into it because he surely knows already that there are patients on SOC that live beyond the “median” overall survival rate, and therefor more than likely must have longer PFS than the median. However, Avastin did provide a PFS advantage without showing an OS advantage. So it’s perhaps a vague question to begin with.